All In Biotech

Drug Trial Radar · NCT06880848

Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

A Prospective, Open-Label, Single-Arm, Multi-Center, Phase IV Efficacy and Safety Study of Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

160

Actual

Start

Jun 21, 2023

Primary completion

Aug 26, 2025

Study completion Aug 26, 2025

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
Collaborators
Sun Pharmaceutical Industries Limited; Zhejiang Hangyu Pharmaceutical Co., Ltd.
First posted
Mar 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation therapy, curative surgery or other local therapies.

Conditions

  • Carcinoma, Basal Cell (BCC)

Interventions

  • Sonidegib Phosphate CapsulesDrug

    Sonidegib should be taken 1 hour before or 2 hours after a breakfast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.